X


See our webpage about the GA-map® product platform

 

Visit page
Skip to content
Genetic Analysis
Genetic Analysis
  • Home
  • About us
    • How we work
    • Management
    • Board of Directors
    • Partnerships
  • Products
    • Service Products
      • The GA-map® Dysbiosis Test Lx
      • The GA-map® COVID-19 Fecal Test Kit
    • Lab Products
      • The GA-map® Dysbiosis Lx reagent kit
      • The GA-map® COVID-19 reagent kit
  • News
    • Press Releases
    • News
  • For Investors
    • Subsequent Offering 2025
    • Financial Reports
    • Financial Calendar
    • Share Information
    • Shareholders
    • Analyst Coverage
    • IPO 2021
    • Corporate Governance
    • Primary Insiders
    • IR Contacts
    • Mailing List
  • Contact us
Genetic Analysis
  • Home
  • About us
    • How we work
    • Management
    • Board of Directors
    • Partnerships
  • Products
    • Service Products
      • The GA-map® Dysbiosis Test Lx
      • The GA-map® COVID-19 Fecal Test Kit
    • Lab Products
      • The GA-map® Dysbiosis Lx reagent kit
      • The GA-map® COVID-19 reagent kit
  • News
    • Press Releases
    • News
  • For Investors
    • Subsequent Offering 2025
    • Financial Reports
    • Financial Calendar
    • Share Information
    • Shareholders
    • Analyst Coverage
    • IPO 2021
    • Corporate Governance
    • Primary Insiders
    • IR Contacts
    • Mailing List
  • Contact us

Eilert Aamodt

Genetic Analysis announces terms of the previously announced subsequent offering to shareholders of up to appr. NOK 9 million

2023-11-30

Genetic Analysis AS offentliggör utfall i optionsinlösen

2023-11-23

Outcome TO2 options warrants

Mandatory notification of trade

2023-11-20

Minutes from the Extraordinary General Meeting

2023-11-20

Presentation of GA-map® by Genetic Analysis sparks great interest at xMAP® Connect EMEA in Amsterdam

2023-11-16

Genetic Analysis AS participates at Medica 13-16. November 2023

2023-11-15

Notice of Extraordinary General Meeting 2023

2023-11-092023-11-06

Information avseende nyttjandeperiod av teckningsoptioner av serie TO 2 i Genetic Analysis AS

2023-11-03

Correction: Updated intended record date for the intended Subsequent Offering announced in press release, November 2, 2023

2023-11-03

Correction of press release regarding subsequent offer

Subscriptions received in separate tranche of previously announced directed share issue

2023-11-062023-11-03
Post navigation
Older posts
Newer posts
← Previous Page1 … Page3 Page4 Page5 … Page11 Next →

Genetic Analysis AS is providing a CE-marked gut microbiota analysis for testing bacterial imbalance in IBS and IBD patients.

Contact

Phone: +47 48 32 16 10
E-mail: info@genetic-analysis.com
Address: Genetic Analysis AS, Ulvenveien 80B
0581 Oslo, Norway

Open Google Maps
Connect

LinkedIn

Facebook

Twitter

Navigate

Contact Us

Terms of Use

Privacy Policy

© 2023 Genetic Analysis

  • Home
  • About us
    • How we work
    • Management
    • Board of Directors
    • Partnerships
  • Products
    • Service Products
      • The GA-map® Dysbiosis Test Lx
      • The GA-map® COVID-19 Fecal Test Kit
    • Lab Products
      • The GA-map® Dysbiosis Lx reagent kit
      • The GA-map® COVID-19 reagent kit
  • News
    • Press Releases
    • News
  • For Investors
    • Subsequent Offering 2025
    • Financial Reports
    • Financial Calendar
    • Share Information
    • Shareholders
    • Analyst Coverage
    • IPO 2021
    • Corporate Governance
    • Primary Insiders
    • IR Contacts
    • Mailing List
  • Contact us